Novel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population. Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur.
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management
Mugheddu C.Primo
Membro del Collaboration Group
;Pizzatti L.Secondo
Membro del Collaboration Group
;Atzori L.
Penultimo
Writing – Review & Editing
;Rongioletti F.Ultimo
Supervision
2020-01-01
Abstract
Novel coronavirus 2019 (SARS-CoV2) pandemic has particularly affected Italy, with a profound impact on the therapeutic strategy for complex disorder such as psoriasis, whose extensive skin damage might expose to an increased infective risk compared to the general population. Psoriasis treatment relies on immunosuppression, and although most experts agree that the benefit-to risk-ratio is in favor of maintaining selective biologic therapies, and small molecules such as apremilast, they recommend dismission if severe COVID-19 symptoms occur.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
apremilast covid oligodendroglioma.pdf
Solo gestori archivio
Tipologia:
versione editoriale (VoR)
Dimensione
552.3 kB
Formato
Adobe PDF
|
552.3 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.